These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7206051)

  • 1. Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder.
    Jakse G; Hofstädter F; Marberger H
    J Urol; 1981 Feb; 125(2):185-90. PubMed ID: 7206051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracavitary doxorubicin hydrochloride treatment for carcinoma in situ of the urinary bladder. A comparative study of two therapy regimens.
    Jakse G
    Eur Urol; 1981; 7(2):68-72. PubMed ID: 7461006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a followup.
    Jakse G; Hofstädter F; Marberger H
    J Urol; 1984 Jan; 131(1):41-2. PubMed ID: 6690744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical doxorubicin hydrochloride in the management of carcinoma in situ of the bladder.
    Jakse G; Hofstädter F
    Eur Urol; 1980; 6(2):103-6. PubMed ID: 7358059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
    Jakse G
    Eur Urol; 1984; 10(5):289-93. PubMed ID: 6440791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells.
    Jakse G; Hofstädter F
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S74-8. PubMed ID: 6640839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder.
    Ek A; Hellsten S; Henrikson H; Idwall I; Lindholm CE; Lindholm K; Mikulowski P; Månsson W
    Scand J Urol Nephrol; 1984; 18(2):131-4. PubMed ID: 6463596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma.
    Garnick MB; Schade D; Israel M; Maxwell B; Richie JP
    J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride.
    Jakse G; Hofstädter F
    Urol Res; 1981; 9(3):153-6. PubMed ID: 7257030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical therapy with adriamycin in patients with superficial bladder tumors.
    Edsmyr F; Berlin T; Boman J; Duchek M; Esposti PL; Gustafsson H; Wijkström H; Collste LG
    Eur Urol; 1980; 6(3):132-6. PubMed ID: 7378141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
    Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H
    J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical chemotherapy in urinary bladder cancer.
    Edsmyr F; Anderson L; Esposti PL
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S67-8. PubMed ID: 6640837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical instillation with adriamycin + tween 80 in patients with superficial bladder tumors: a preliminary report.
    Eksborg S; Edsmyr F; Näslund I
    Eur Urol; 1982; 8(4):213-5. PubMed ID: 7094962
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder.
    Banks MD; Pontes JE; Izbicki RM; Pierce JM
    J Urol; 1977 Nov; 118(5):757-60. PubMed ID: 916094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin).
    Glashan RW
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S35-7. PubMed ID: 6640833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder.
    Fukui I; Sekine H; Kihara K; Yamada T; Takeuchi S; Yokokawa M; Kawai T; Hosoda K; Ohwada F; Suzuki S
    J Urol; 1989 Mar; 141(3):531-4. PubMed ID: 2493099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study.
    Jauhiainen K; Sotarauta M; Permi J; Alfthan O
    Eur Urol; 1986; 12(1):32-7. PubMed ID: 3081351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical instillaton of adriamycin: treatment of patients with difficulties to retain the instilled liquid.
    Näslund I; Eksborg S
    Eur Urol; 1981; 7(5):318. PubMed ID: 7250166
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
    Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
    J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.